These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16910543)

  • 1. [Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].
    Suzuki Y; Sawamura H; Someya T
    Seishin Shinkeigaku Zasshi; 2006; 108(6):633-41. PubMed ID: 16910543
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbamazepine and/or fluvoxamine drug interaction with risperidone in a patient on multiple psychotropic medications.
    Alfaro CL; Nicolson R; Lenane M; Rapoport JL
    Ann Pharmacother; 2000 Jan; 34(1):122-3. PubMed ID: 10669197
    [No Abstract]   [Full Text] [Related]  

  • 5. Extrapyramidal symptoms after addition of fluvoxamine to clozapine.
    Kuo FJ; Lane HY; Chang WH
    J Clin Psychopharmacol; 1998 Dec; 18(6):483-4. PubMed ID: 9864083
    [No Abstract]   [Full Text] [Related]  

  • 6. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
    Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
    Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
    Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J
    Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of olanzapine with fluvoxamine.
    de Jong J; Hoogenboom B; van Troostwijk LD; de Haan L
    Psychopharmacology (Berl); 2001 May; 155(2):219-20. PubMed ID: 11401013
    [No Abstract]   [Full Text] [Related]  

  • 10. [Customized pharmacotherapies in schizophrenia].
    Suzuki Y; Fukui N; Watanabe J; Ono S; Sugai T; Tsuneyama N; Someya T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):77-81. PubMed ID: 20491281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptoms of agitated depression and/or akathisia.
    Peitl MV; Prološčić J; Blažević-Zelić S; Skarpa-Usmiani I; Peitl V
    Psychiatr Danub; 2011 Mar; 23(1):108-10. PubMed ID: 21448111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenetic challenges in the treatment of mental diseases].
    Sukhanov VA; Piruzian LA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(8):83-6. PubMed ID: 15554149
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical pharmacogenetics in the treatment of schizophrenia].
    Saito M; Yasui-Furukori N; Kaneko S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine in the treatment of resistant depression.
    Caetano D; Caetano SC
    Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
    [No Abstract]   [Full Text] [Related]  

  • 16. Dosing strategies of clozapine-fluvoxamine cotreatment.
    Lu ML; Lane HY; Jann MW; Chang WH
    J Clin Psychopharmacol; 2002 Dec; 22(6):626-8. PubMed ID: 12454566
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
    Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
    J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients.
    Silver H; Susser E; Danovich L; Bilker W; Youdim M; Goldin V; Weinreb O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):573-84. PubMed ID: 21208484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients.
    Arranz B; Rosel P; San L; Ramírez N; Dueñas RM; Salavert J; Centeno M; del Moral E
    Psychiatry Res; 2007 Oct; 153(2):103-9. PubMed ID: 17629952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
    Peñas-Lledó EM; Dorado P; Cáceres MC; de la Rubia A; Llerena A
    Clin Chem Lab Med; 2007; 45(7):835-8. PubMed ID: 17617023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.